3billion Partners with Kazakhstan’s CMM to Expand Rare Disease Diagnostics

3billion, announced on the 25th that it has signed a strategic partnership with the Center for Molecular Medicine (CMM), the largest genome-specialized medical institution in Kazakhstan, to expand access to rare disease genetic testing services.

Founded in 2003, CMM has been at the forefront of Kazakhstan’s genetic medicine field and operates the nation’s largest genetic counseling and diagnostics network. Kazakhstan is currently one of the fastest-growing markets for rare disease diagnostics in Central Asia, with 3billion’s local sales surging by 233% in the first half of 2025 compared to the same period last year, underscoring the strong market potential.

Through this agreement, 3billion will integrate its proprietary AI technology into CMM’s extensive counseling and diagnostics network. The company will provide next-generation sequencing (NGS)-based Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) services to CMM. Leveraging over 80,000 accumulated global rare disease diagnostic cases, 3billion’s AI-powered variant interpretation models will further enhance diagnostic accuracy and efficiency.

In addition, 3billion has been officially invited to present at the Annual Meeting of the Association of Medical Genetics of Kazakhstan (AMGK), hosted by CMM from September 23–26. At the event, the company will share clinical success stories using its testing services, strengthening credibility among Kazakhstan’s leading medical professionals and setting the stage for broader expansion across Central Asia.

Sookjin Lee, Chief Business Officer of 3billion, stated:
“Demand for rare disease diagnostics is rapidly increasing in Kazakhstan. Our collaboration with CMM will expand diagnostic opportunities for both local physicians and patients, while laying the foundation for sustainable growth across the Central Asian region.”